The Claim
In European patients with biopsy-proven non-alcoholic fatty liver disease, the SIRT5 rs12216101 T>G genetic variant is significantly associated with an increased risk of non-alcoholic steatohepatitis and moderate-to-severe liver fibrosis (F2-F4), with adjusted odds ratios of 1.20 and 1.18 respectively, after controlling for age, sex, diabetes, and PNPLA3 rs738409 genotype status.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A certain gene change (SIRT5 rs12216101) might make it more likely for some Europeans with fatty liver disease to develop serious liver inflammation and scarring, even after accounting for other known risk factors.
See the scientific wording
The SIRT5 rs12216101 T>G genetic variant is associated with increased risk of non-alcoholic steatohepatitis and moderate-to-severe liver fibrosis (F2-F4) in European patients with biopsy-proven non-alcoholic fatty liver disease, with odds ratios of 1.20 and 1.18 respectively, after adjusting for age, sex, diabetes, and PNPLA3 rs738409 status.
What the research says
1 studyThe study found that people with a specific gene change (SIRT5 rs12216101 T>G) had a higher risk of serious liver disease, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.